Drug Trial Radar · NCT03866980
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
164
Actual
Start
Nov 27, 2018
Primary completion
Jun 30, 2023
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- Collaborators
- Akeso Tiancheng, Inc
- First posted
- Mar 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III , randomized, double-blinded, multicenter clinical study to compare efficacy and safety of AK105 (Anti-PD1 antibody) combined with Carboplatin and Pemetrexed vs Placebo combined with Carboplatin and Pemetrexed as first-line therapy in patients with EGFR and ALK wild type metastatic nonsquamous non-small cell lung cancer.
Conditions
- Lung Cancer Non-small Cell Stage IV
Interventions
AK105Biological
IV infusion
carboplatinDrug
IV infusion
pemetrexedDrug
IV infusion
placeboDrug
IV infusion
AnlotinibDrug
PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1Time frame: up to 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.